<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402207</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 05-005</org_study_id>
    <nct_id>NCT00402207</nct_id>
  </id_info>
  <brief_title>The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry</brief_title>
  <official_title>The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Exhaled Nitric Oxide, Inflammatory Markers in Exhaled Breath Condensate and Conventional Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Branded</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <brief_summary>
    <textblock>
      Background Chronic inflammation in peripheral airways plays an important role in the&#xD;
      pathophysiology of asthma. Extrafine hydrofluoroalkane (HFA) beclometasone is distinguished&#xD;
      from other ICS because of its fine aerosol characteristics. As a result, there is a greater&#xD;
      extent of deposition of extrafine HFA-beclometasone in the peripheral airways. Therefore,&#xD;
      extrafine HFA-beclometasone may have an extra anti-inflammatory effect in children with&#xD;
      asthma.&#xD;
&#xD;
      Aim To analyse the potential extra anti-inflammatory effect of extrafine HFA-beclometasone&#xD;
      compared to HFA-flucticasone in children with asthma by means of alveolar nitric oxide (NO)&#xD;
      concentration and bronchial NO flux, inflammatory markers in exhaled breath condensate (EBC),&#xD;
      and conventional parameters.&#xD;
&#xD;
      Method In a cross-over study design of 6 months, 33 children, aged 6-12 years, with doctor&#xD;
      diagnosed mild persistent asthma, were treated with extrafine HFA-beclometasone inhaled from&#xD;
      an autohaler and HFA-flucticasone inhaled from a discus. Primary outcome parameters of this&#xD;
      study were; alveolar NO concentration and bronchial NO flux. Secondary outcome parameters&#xD;
      were inflammatory markers in EBC, lung function parameters, symptoms, presence and duration&#xD;
      of exacerbations and adverse effects. All parameters were recorded at baseline and after each&#xD;
      treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date>October 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>status of airway inflammation after a 3 months treatment period</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>alveolar and bronchial exhaled nitric oxide</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers in exhaled breath condensate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lung function parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptoms / symptom free days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
  </secondary_outcome>
  <enrollment>33</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extrafine HFA-beclomethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HFA-fluticasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 6.5 - 12 years&#xD;
&#xD;
          -  children with mild-persistent asthma&#xD;
&#xD;
          -  treatment with inhaled corticosteroids(≤ 500 μg HFA-Flucticasone, ≤ 800 μg Budesonide,&#xD;
             or ≤ 800 μg HFA-Beclometasone, daily)&#xD;
&#xD;
          -  allowed, but needed to be used during the entire study period;&#xD;
&#xD;
               -  short / long-acting β2-agonists&#xD;
&#xD;
               -  leukotrien receptor antagonists&#xD;
&#xD;
               -  antihistamines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Instability of asthma during the past 3 months&#xD;
&#xD;
          -  Presence of a disease that may intervene with the results of this study&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  Inability to perform the measurements properly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>78 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte M Robroeks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rijn Jöbsis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Dompeling, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>November 20, 2006</last_update_submitted>
  <last_update_submitted_qc>November 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2006</last_update_posted>
  <keyword>asthma</keyword>
  <keyword>non-invasive inflammometry</keyword>
  <keyword>exhaled nitric oxide</keyword>
  <keyword>exhaled breath condensate</keyword>
  <keyword>paediatric</keyword>
  <keyword>extrafine HFA-beclomethasone</keyword>
  <keyword>HFA-fluticasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

